The EANM guideline on radioiodine therapy of benign thyroid disease
European journal of nuclear medicine and… · 2023 · DACH
Source and licence
- Authors
- Alfredo Campennì, Anca M Avram, Frederik A Verburg et al.
- Title
- The EANM guideline on radioiodine therapy of benign thyroid disease
- Journal
- European Journal of Nuclear Medicine and Molecular Imaging, 2023
- Licence
- CC BY 4.0
- Changes
- Verbatim excerpts; formatting adapted
Full text retrieved 2026-10-27 from Europe PMC · PMC10542302
Licence statement of the original publication
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
This page reproduces excerpts of the original publication; the original is authoritative. It has not been reviewed by a physician, does not state a recommendation of Medelix and does not replace medical advice. The guideline may have been updated since.
Open the original publication →Full text on Europe PMC
Recommendations
We found no explicitly labelled recommendations in this publication; its recommendations are in the running text of the original.
Abstract
This document provides the new EANM guideline on radioiodine therapy of benign thyroid disease. Its aim is to guide nuclear medicine physicians, endocrinologists, and practitioners in the selection of patients for radioiodine therapy. Its recommendations on patients’ preparation, empiric and dosimetric therapeutic approaches, applied radioiodine activity, radiation protection requirements, and patients follow-up after administration of radioiodine therapy are extensively discussed.
Contents of the original publication
The section headings of the original.
- Preamble
- Autoimmune hyperthyroidism (Graves’ disease) and non-autoimmune toxic nodular goiter/toxic multinodular goiter
- Introduction
- Radionuclides of interest for thyroid imaging and therapy
- General considerations for RAI therapy
- Definition of Graves’ disease, toxic nodular goiter, toxic multinodular goiter
- Diagnostic approaches and alternative treatments
- Radioiodine therapy in autoimmune and non-autoimmune hyperthyroid patients
- RAI therapy for patients with autoimmune hyperthyroidism (Graves’ disease)
- Introduction
- Definition and epidemiology
- Indication and contraindications (absolute and relative)
- Concepts for RAI therapy delivery in Graves’ disease: functional vs. ablative
- RAI therapy for patients affected by non-autoimmune toxic nodular goiter/toxic multinodular goiter
- Introduction
- Definition and epidemiology
- Indications and contraindications (absolute and relative)
- RAI therapy for non-autoimmune toxic nodular goiter /toxic multinodular goiter
- RAI therapy for patients with non-toxic goiter
- Introduction
- Definition and epidemiology
- Indications and contraindications for RAI therapy in NTG
- RAI therapy approach for NTG patients
- RAI therapy delivery for treatment of non-toxic goiter
- RAI therapy in pediatric patients
- Special considerations for RAI therapy in children
- Therapeutic concepts
- Side effects in pediatric patients
- Alternative treatment
- Adverse effects of RAI therapy
- Early side effects
- Late side effects
- Pregnancy following RAI treatment
A question about this guideline?
Medelix answers clinical questions from guidelines and studies – every statement with its source.
Are you the rights holder and object to this reproduction? Write to contact@medelix.ai and we will take the page down promptly. Imprint